Insmed Inc
Q3 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +0.25%.
Did INSM Beat Earnings? Q3 2025 Results
Insmed delivered a strikingly mixed Q3 2025, with revenue soaring 52.4% year over year to $142.34 million, well ahead of the $115.49 million consensus, while its per-share loss of $1.75 missed the $-1.367 estimate by 28.02% as the company absorbed the heavy costs of launching its newly approved BRINSUPRI. The FDA-approved DPP1 inhibitor, the first treatment authorized for non-cystic fibrosis bronchiectasis, generated $28.10 million in net sales during its partial debut quarter, drawing roughly 2,550 patients and prescriptions from approximately 1,700 physicians, though management noted that inventory stocking accounted for about 40% of those sales and is unlikely to repeat at that level in Q4. ARIKAYCE, meanwhile, posted $114.30 million in quarterly revenue, up 22% year over year, prompting Insmed to raise its full-year ARIKAYCE guidance to $420 million–$430 million. Total operating expenses climbed to $508.35 million, driven by a $104.65 million fair-value charge and near-doubling SG&A costs, widening the net loss to $370.02 million. With a positive EMA recommendation already secured and regulatory submissions accepted in the UK and Japan, international BRINSUPRI launches in 2026 represent the next major commercial catalyst for the company.
- FDA approval and U.S. launch of BRINSUPRI drove new revenue stream ($28.1M in partial quarter)
- ARIKAYCE global revenue grew 22% YoY with record quarterly results in both U.S. and international markets
- International ARIKAYCE business grew 52% YoY driven by expansion across all geographic regions
- ~2,550 patients started BRINSUPRI treatment and ~1,700 physicians wrote prescriptions in the partial quarter
“The third quarter of 2025 celebrated the FDA approval of BRINSUPRI and the availability of our second commercial product, underscoring our team's dedication to bringing forward a first-in-disease therapy for patients with non-cystic fibrosis bronchiectasis. While still early in the U.S. BRINSUPRI launch, we are very encouraged by positive feedback received from both physicians and patients.”
Insmed CEO, on the earnings call
Forward Guidance & Outlook
Insmed raised its full-year 2025 global ARIKAYCE revenue guidance to $420 million to $430 million (from $405 million to $425 million previously), representing 15% to 18% year-over-year growth compared to 2024. For BRINSUPRI, the company expects the first full quarter (Q4 2025) to provide a clearer picture of underlying launch dynamics, noting that inventory stocking (~40% of Q3 sales) is not expected to be as impactful in Q4. The company anticipates multiple clinical catalysts over the next 18 months: Phase 2b BiRCh topline data (CRSsNP) by early January 2026, Phase 2b CEDAR topline data (HS) in H1 2026, ENCORE Phase 3 topline data (ARIKAYCE label expansion) in H1 2026, PALM-ILD Phase 3 initiation in Q4 2025, and additional Phase 3 TPIP studies in PAH, PPF, and IPF in 2026. International BRINSUPRI launches are anticipated in the EU, UK, and Japan in 2026 pending regulatory approvals.
INSM YoY Financials
INSM Revenue by Segment
INSM Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.